GLP-1s Beyond Weight Loss: What's Proven, What's Promising, and What's Just a Headline

Educational journalism, not medical advice. Every claim here is checked against its cited sources by editor Tim Bunce — a health writer, not a physician. It isn’t specific to your situation: for health decisions, talk to your own clinician. How we work →

Why an “evidence ladder”

Almost every viral GLP-1 claim is technically “backed by a study” — but the studies are wildly different in strength. A randomised controlled trial that assigns thousands of people to drug or placebo and follows them for years is the gold standard. A real-world analysis that compares people who happened to take a drug with those who didn’t is useful but weaker, because the two groups differ in ways that are hard to fully account for. So instead of a flat list of benefits, here is the evidence ranked by how sure we actually are.

Top rung: the heart (SELECT)

The SELECT trial randomised 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes to weekly semaglutide (2.4 mg) or placebo. Over roughly 40 months, major adverse cardiovascular events — cardiovascular death, heart attack, or stroke — occurred in 6.5% on semaglutide versus 8.0% on placebo: a 20% relative risk reduction (hazard ratio 0.80) Lincoff 2023.

This is strong evidence — a large, double-blind RCT. Two honest caveats: the absolute difference was 1.5 percentage points (the “20%” is relative), and it applies to people who already have heart disease plus excess weight, not the general population. It was also funded by the manufacturer, Novo Nordisk — worth knowing, though the design is robust.

Top rung: the kidneys (FLOW)

The FLOW trial tested semaglutide in 3,533 people with type 2 diabetes and chronic kidney disease, and was stopped early for clear benefit. Compared with placebo, semaglutide cut the primary composite of major kidney events and cardiovascular death by 24% (hazard ratio 0.76), reduced major cardiovascular events by 18%, and lowered all-cause mortality by 20% Perkovic 2024.

Again: a large RCT, genuinely practice-changing for kidney medicine. And again the boundaries matter — this was people with both diabetes and kidney disease, a high-risk group, not healthy adults. Trials stopped early for benefit can also modestly overstate the effect size, so read it as “clearly helpful in this population,” not “a precise number for everyone.”

A rung down: the real-world signals

Beyond the trials, large analyses of medical records are flagging other associations. One 2026 study in the Journal of the American Heart Association emulated a trial using records from 26,408 adults with obesity and an autoimmune disease, and found GLP-1 use linked to a 44% lower risk of death, a 31% lower risk of pulmonary embolism, a 21% reduction in emergency-department visits, and a 17% lower risk of venous blood clots Sheer 2026.

Those numbers are striking — and exactly the kind that demand caution. This is observational data, not a randomised trial; the authors themselves say it cannot prove cause and effect, and better weight or blood-sugar control may explain much of it. People who take and tolerate a medication also tend to be healthier in ways records can’t capture (“healthy-user bias”). Treat a 44% mortality figure from record-keeping as a hypothesis worth testing, not a proven benefit. (In the same analysis, stroke and heart-attack reductions were small or not statistically significant — so don’t add those to the list.)

Bottom rung: the addiction frontier

GLP-1 receptors sit in the brain’s reward circuitry, and the drugs appear to dampen the dopamine-driven “wanting” that fuels cravings — which is why some people report spontaneously drinking, smoking, or snacking less. Researchers including a group led by Dr. Joji Suzuki at Brigham and Women’s Hospital are running clinical trials of GLP-1s for alcohol and opioid use disorders, and small early trials have hinted at reduced cravings Harvard Gazette 2026.

This is the most exciting and the least settled rung. As of now there is no approved use of GLP-1s for any addiction; the trials are ongoing and the existing studies are small. File it under “a genuinely interesting frontier,” not “a treatment you can ask for.”

The part the headlines skip

None of this means a GLP-1 is a good idea for everyone:

• They’re prescription drugs. The right candidate, dose, and monitoring are a clinical decision. The trial doses above are study design, not advice.
• Side effects are common and real. In SELECT, adverse events leading to permanent discontinuation hit 16.6% on semaglutide versus 8.2% on placebo — roughly double — mostly gastrointestinal (nausea, vomiting, diarrhoea) Lincoff 2023.
• The biggest trials are manufacturer-funded. That doesn’t invalidate them, but it’s worth knowing.
• The benefits above were in already-sick populations. “Off-label benefits” framing shouldn’t read as “everyone should take these.”

The bottom line

GLP-1s have earned the “more than weight loss” reputation — but the strength of the evidence drops fast as you go down the ladder. Two big randomised trials genuinely proved heart and kidney benefits in specific high-risk groups. The eye-catching extras — a 44% lower death rate in obesity-plus-autoimmune disease, or quieter addiction cravings — come from observational data or early trials, so they’re leads to watch, not facts to bank on. If a GLP-1 might be right for you, that’s a conversation with your doctor about your specific risks — not a decision to make from a headline.

This article is educational, not medical advice. GLP-1 medications are prescription-only; never start, stop, or change a medication without your prescribing clinician.

How these drugs actually work

To judge what GLP-1s can and cannot do, it helps to know what they are. GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after a meal. It is an incretin — a signal that tells the pancreas, the brain, and the stomach that food has arrived. Drugs like semaglutide and tirzepatide are engineered, longer-lasting copies of this signal, so they keep that "you've just eaten" message switched on for days at a time. A 2024 review in Frontiers in Endocrinology lays out the four levers they pull: they prompt the pancreas to release insulin only when blood sugar is high, they quiet the hormone (glucagon) that pushes sugar up, they slow how fast the stomach empties, and they act directly on appetite centres in the brain such as the hypothalamus and the area postrema Liu 2024. That last lever is why people describe "food noise" going quiet.

This biology is the reason a weight-loss drug keeps turning up in headlines about hearts, kidneys, and livers. GLP-1 receptors sit on many tissues beyond the gut, so the same molecule that dampens appetite also nudges blood pressure, inflammation, and how the body handles fat. But — and this is the honest caveat — a plausible mechanism is not proof of benefit. Biology tells you why an effect might exist; only the randomised trials further up the evidence ladder tell you whether, and for whom, it actually does Liu 2024.

For the heart, that trial exists. The SELECT trial randomised 17,604 adults who had cardiovascular disease and excess weight but not diabetes; over about three years, semaglutide cut major cardiovascular events — heart attack, stroke, or cardiovascular death — by roughly 20% (6.5% vs 8.0%) Lincoff 2023. For the kidneys, the FLOW trial in people with type 2 diabetes and chronic kidney disease was stopped early after semaglutide reduced major kidney-disease events by about 24% Perkovic 2024. These randomised results — not the mechanism story alone — are what regulators relied on, and they are why the heart and kidney uses sit on far firmer ground than most of the claims that circulate online.

Two more proven uses you'll hear less about

Beyond heart and kidney disease, two further "beyond weight loss" uses have now cleared the top rung — randomised, placebo-controlled trials — and both are easy to miss in the noise. The first is sleep apnoea. In the SURMOUNT-OSA trials, adults with moderate-to-severe obstructive sleep apnoea (where the airway repeatedly collapses during sleep) and obesity took tirzepatide for a year. The number of breathing interruptions per hour — the apnoea–hypopnoea index — fell by about 20 to 24 more events per hour than with placebo, a clinically meaningful drop alongside weight, blood-pressure, and inflammation improvements Malhotra 2024. On that evidence, US regulators added obstructive sleep apnoea to tirzepatide's approved uses.

The second is the liver. In the phase-3 ESSENCE trial, people with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH — a fatty, inflamed, scarring liver) took semaglutide for 72 weeks. Inflammation resolved without the scarring getting worse in 62.9% on the drug versus 34.3% on placebo, and the scarring itself improved in 36.8% versus 22.4% Sanyal 2025. These are genuine high-quality findings — but note the pattern that runs through this whole article: the benefit was measured in a specific, already-affected group (people with proven liver disease on biopsy), not the general public, and the trial's primary read-out was an interim analysis of the first 800 of roughly 1,200 participants Sanyal 2025.

The muscle question — and what happens when you stop

Rapid weight loss never removes only fat; some lean tissue, including muscle, goes too. This matters for older adults and anyone worried about long-term strength. The SEMALEAN study followed people with obesity on semaglutide for a year and found lean mass dropped by about 3 kg in the first seven months and then held steady, while fat mass fell roughly 14% at seven months and 19% at twelve Alissou 2026. Reassuringly, grip strength actually rose (by about 4 kg) and the share of people classed as having "sarcopenic obesity" — obesity plus low muscle function — fell from 49% to 33% Alissou 2026. The likely reason is simple: carrying far less weight lightens the load on the muscle that remains. The practical takeaway most clinicians draw is to pair the drug with adequate protein and resistance exercise to protect muscle, though that combination has not yet been proven to change hard outcomes.

The bigger unknown is what happens after you stop. In the STEP 1 trial extension, participants who had lost an average of 17% of their body weight on semaglutide came off the drug. One year later they had regained about two-thirds of what they had lost — roughly 11.6 percentage points back, leaving a net loss of about 5.6% — and most of the early improvements in blood pressure, blood sugar, and cholesterol drifted back toward where they started Wilding 2022. The lesson is not that the drugs fail; it is that obesity behaves like a chronic condition, and the benefits last only as long as treatment does Wilding 2022. That reframes every "proven benefit" above as something that may need to be maintained indefinitely, with the costs and side-effect exposure that implies.

Who should be cautious — and the conversation to have

None of this is a reason to start, or avoid, these medicines on your own; that is a decision for you and a clinician who knows your history. But it is worth knowing where the genuine cautions lie. The official Wegovy (semaglutide) prescribing label carries a boxed warning about thyroid C-cell tumours seen in rodents and lists a firm contraindication: people with a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN 2 should not take it DailyMed 2026. The label also flags acute pancreatitis (inflammation of the pancreas), gallbladder disease, and advises against use in severe gastroparesis (a stomach that already empties too slowly), and it instructs that the drug be stopped if pregnancy is recognised, because animal studies showed possible harm to the fetus and weight loss offers a pregnant patient no benefit DailyMed 2026.

How serious are these in practice? Here the evidence is reassuring but not blank. The gut side effects — nausea, vomiting, diarrhoea — are by far the most common, tend to be dose-related, and ease for many people over time Huang 2025. Gallstones are a real, if uncommon, signal: a meta-analysis of 76 randomised trials found GLP-1 use raised the risk of gallbladder or biliary disease by about a third, with the risk running higher at the bigger doses used for weight loss and with longer treatment He 2022. Pancreatitis is the one that worries patients most, yet the trial evidence is more reassuring than the fear suggests: pancreatic enzyme (amylase and lipase) levels can rise on treatment, but those elevations poorly predict actual pancreatitis, and pooled randomised trials have not found a statistically significant increase in pancreatitis cases versus placebo Mehta 2025. The honest summary: the common effects are manageable and usually temporary, the dangerous ones are rare but worth screening for, and anyone who is pregnant, planning pregnancy, or living with thyroid, pancreatic, or gallbladder conditions should treat that screening conversation as non-negotiable.

Wondering how the two big drugs compare? See our cited head-to-head of Ozempic vs Mounjaro (semaglutide vs tirzepatide).

Seen berberine called ‘nature’s Ozempic’? Here’s the honest berberine vs Ozempic comparison.

Tempted by ‘research peptides’? See what the evidence (and the FDA) say about BPC-157 and friends.

References